Otherwise, no significant improvement in terms of ORR, progression-free survival, and overall survival have been observed, and in particularly after treatment with the MEK inhibitor selumetinib in metastatic pretreated KRAS-mutated NSCLC [23]. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.